(HealthDay News) — For immunocompetent adults with recurrent Clostridioides difficile infection (rCDI), fecal microbiota transplantation (FMT) yields a significant increase in resolution compared with alternative treatments, according to a review published online April 25 in the Cochrane Library.
Nathan Zev Minkoff, MD, from Valley Children’s Hospital in Madera, CA, and colleagues examined the benefits and harms of donor-based FMT for treatment of rCDI in immunocompetent adults versus placebo, autologous FMT, no intervention or antibiotics. Data were pooled from six studies with 320 adult participants.
The researchers found that use of FMT in immunocompetent participants with rCDI likely leads to a large increase in resolution of rCDI compared with control (risk ratio, 1.92; 95% confidence interval, 1.36 to 2.71; P = 0.02). FMT probably yields a slight reduction in serious adverse events, but the investigators did not find a significant association (risk ratio, 0.73; 95% confidence interval, 0.38 to 1.41; P = 0.24). FMT may reduce the risk for all-cause mortality, but the number of events was small and confidence intervals were wide (risk ratio, 0.57; 95% confidence interval, 0.22 to 1.45; P = 0.48).
“The risk of recurrence increases to about 40% with the second episode and to nearly 60% with the third episode. So, once you are in this cycle, it gets more and more difficult to break out of it,” a coauthor said in a statement. “Stool transplants can reverse the dysbiosis and thus decrease the risk of recurrence of the disease.”
Abstract/Full Text (subscription or payment may be required)
